Ceapro Inc. announced that it presented very promising data from its collaboration study of the immunoregulatory effect of oat avenanthramides during downhill running in young men and women at the Annual World Congress of the American College of Sports Medicine (ACSM), held May 28-June 1, 2019 in Orlando, Florida. The Company previously announced positive results on the anti-inflammatory properties of avenanthramides at the American Society for Nutrition's meeting, Nutrition 2018, which showed that oat avenanthramides upplementation reduces circulatory inflammation and inhibits expressions of chemokines and adhesion molecules. The objective of this study was to evaluate the effects of oat avenanthramides supplementation on the underlying mechanism of eccentric exercise- induced inflammation as measured by leukocytes levels changes in the blood of human subjects. The study evaluated 24 subjects that were assigned to a high avenanthramides group or low avenanthramides group. Two treadmill-based downhill running sessions were separated by 8-week washout period followed by 8-weeks of oat avenanthramides supplementation through receiving two cookies containing high or low concentration of avenanthramides daily. Blood samples were collected before downhill running and at various time points (0 hours, 4 hours, 24 hours, 48 hours, 72 hours) after downhill running. Results showed that high regimen of avenanthramides could inhibit exercise-induced colony stimulating factors (G-CSF) and decreased circulatory monocytes (CD14) and neutrophils (CD 11b) and increased NK cells (CD56). The manuscript of this study is under final revision by the authors and the co-sponsoring companies, Ceapro Inc. (AB, Canada) and PepsiCo (USA).